Author:
Bensimon Corinne,Redshaw Russell
Reference77 articles.
1. Axworthy DB, Reno JM, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, Su F, Hobson LJ, Beaumier PL, Fritzberg AR (2000) Cure of human carcinoma xenografts by a single dose of pretargeted yttrium 90 with negligible toxicity. Proc Natl Acad Sci U S A 97:1802–1807
2. Bolton AE, Hunter WM (1973) The labeling of proteins to high specific radioactivity by conjugation to a 125I- containing acylating agent. Biochem J 133:529–538
3. Broan CJ, Cox JPL, Craig AS, Kataky R, Parker D, Harrison A, Randall AM, Ferguson G (1991) J Chem Soc Perkin Trans 2:87–99
4. Buchanan L, Jurek P, Redshaw R (2007) Nuclear imaging drug development tools. GEN 27:23–25
5. Camera L, Kinuya S, Garmestani K, Wu C, Briechbiel MW, Pai LH, McMurry TJ, Gansow OA, Pastan I, Paik CH et al (1994) Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med 35:882–889